Biomm (BIOM3)

Executive Summary

Biomm is a Brazilian biotechnology company focused on developing and manufacturing recombinant protein therapeutics, including insulin and biosimilars for oncology and ophthalmology. Founded in 2020 and publicly traded (BIOM3), the company leverages mammalian cell culture platforms to produce high-quality biologics for Brazil’s public health system and private market. By targeting the growing demand for affordable biologics, Biomm aims to reduce Brazil’s dependence on imported drugs and enhance pharmaceutical autonomy. The company’s product portfolio includes insulin analogs, oncology biosimilars (e.g., bevacizumab, trastuzumab), and ophthalmology biosimilars (e.g., ranibizumab). As a commercial-stage entity, Biomm faces competition from large multinationals but benefits from favorable local regulatory pathways and government support for domestic production. The company’s strategy centers on securing ANVISA approvals, expanding manufacturing capacity, and forging partnerships with the public sector. With a strong focus on cost-effective therapies, Biomm is well-positioned to capture market share in Brazil’s rapidly growing biosimilar market, which is projected to expand due to patent expirations and healthcare cost containment pressures.

Upcoming Catalysts (preview)

• Q4 2026ANVISA approval of insulin glargine biosimilar (Biomm's biosimilar)80% success
• H1 2027Commercial launch of ranibizumab biosimilar for ophthalmology65% success
• Q3 2026Supply agreement with Brazil's Ministry of Health for oncology biosimilars70% success